达比加群酯预防非瓣膜性房颤患者血栓栓塞的有效性和安全性

目的 比较达比加群酯和调整剂量的华法林预防非瓣膜性房颤患者血栓栓塞的有效性和安全性.方法 选取2013年9月至2014年6月收治的166例非瓣膜性房颤患者进行回顾性分析,分为达比加群酯组(110 mg/次,2次/d)和华法林组(初始剂量为2.5 mg/d),国际标准化比值(INR)在2.0~3.0之间.随访6个月,比较两组血栓栓塞事件及出血事件的发生情况.结果 有效性终点指标:达比加群酯组无血栓栓塞事件的发生,华法林组发生缺血性脑卒中1例,两组患者血栓栓塞事件发生率差异无统计学意义(0.0% vs 1.2%, P>0.05);安全性终点指标:两组均无重要出血事件发生,达比加群酯组发生轻微出血事件4例,华法林组发生轻微出血事件5例,两组患者出血事件发生率差异无统计学意义(P>0.05).结论 达比加群酯预防非瓣膜性房颤患者血栓栓塞的有效性和安全性与华法林相当.

Efficacy and safety of dabigatran etexilate versus warfarin in antithrombotic therapy for nonvalvular atrial filbrillation

Objective To compare the efficacy and safety of dabigatran etexilate with warfarin for thromboembolism prevention in patients with nonvalvular atrial fibrillation. Methods A total of 166 patients with nonvalvular atrial fibrillation were identified as dabigatran etexilate group (110 mg, twice daily) and warfarin group (target international normalized ratio, 2.0~3.0). The efficacy and safety of the two drugs were compared in regard to stroke or systemic embolism and major bleeding outcomes during a follow-up of 6 months. Results In the thromboembolism events, there was no significant difference between dabigatran etexilate group and warfarin group (0.0% vs 1.2%, P>0.05). The rate of bleeding was 4.82% in the dabigatran etexilate group, as compared with 6.02% in the warfarin group (P>0.05). Conclusion There are similar thromboembolism and bleeding rates in patients with nonvalvular atrial fibrillation between dabigatran etexilate and warfarin.